Does liver-derived ANGPTL3 play a role in cardiometabolic risk? Current evidence and future perspectives

References

• Sampson UK, Fazio S, Linton MF. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr. Atheroscler. Rep. 14(1), 1–10 (2012).
   Google Scholar
• Boden G. Obesity, insulin resistance and free fatty acids. Curr. Opin. Endocrinol. Diabetes Obes. 18(2), 139–143 (2011).
   Google Scholar
• Arca M, Minicocci I, Maranghi M. The angiopoietin-like protein 3: an hepatokine with expanding role in metabolism. Curr. Opin. Lipidol. 24(4), 313–320 (2013).
   Google Scholar
• Lee EC, Desai U, Gololobov G et al. Identification of a new functional domain in angiopoietin-like 3 (ANGPTL3) and angiopoietin-like 4 (ANGPTL4) involved in binding and inhibition of lipoprotein lipase (LPL). J. Biol. Chem. 284, 13735–13745 (2009).
   Google Scholar
• Shan L, Yu XC, Liu Z et al. The angiopoietinlike proteins ANGPTL3 and ANGPTL4 inhibit lipoprotein lipase activity through distinct mechanisms. J. Biol. Chem. 284, 1419–1424 (2009)
   Google Scholar
• Liu J, Afroza H, Rader DJ et al. Angiopoietin-like protein 3 inhibits lipoprotein lipase activity through enhancing its cleavage by proprotein convertases. J. Biol. Chem. 285, 27561–27570 (2010).
   Google Scholar
• Quagliarini F, Wang Y, Kozlitina J et al. Atypical angiopoietin-like protein that regulates ANGPTL3. Proc. Natl Acad. Sci. USA 109, 19751–19756 (2012). ▪▪ Identifies Angptl8 as an activator of Angptl3. In particular, Angptl8 facilitates Angptl3 proteolytic cleavage and the release of its N-terminal domain, which is responsible for the inhibition of lipoprotein lipase.
   Google Scholar
• Shimamura M, Matsuda M, Kobayashi S et al. Angiopoietin-like protein 3, a hepatic secretory factor, activates lipolysis in adipocytes. Biochem. Biophys. Res. Commun. 301, 604–609 (2003). ▪ Demonstrates that Angptl3 targets adipose cells and induces in vitro lipolysis, and that both plasma free fatty acids (FFAs) and glycerol are decreased in Angptl3-deficient mice, and increased by treatment with human Angptl3. Suggests that Angptl3 is a liver-derived lipolytic hepatokine targeting adipocytes.
   Google Scholar
• Musunuru K, Pirruccello JP, Do R et al. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N. Engl. J. Med. 363, 2220–2227 (2010).
   Google Scholar
• Minicocci I, Montali A, Robciuc M R et al. Mutations in the ANGPTL3 gene and familial combined hypolipidemia: a clinical and biochemical characterization. J. Clin. Endocrinol. Metab. 97, e1266–e1275 (2012).
   Google Scholar
• Pisciotta L, Favari E, Magnolo AL et al. Characterization of three kindred with familial combined hypolipidemia due to loss of function mutations of ANGPTL3. Cardiovasc. Genet. 5, 42–50 (2012).
   Google Scholar
• Martín-Campos JM, Roig R, Mayoral C et al. Identification of a novel mutation in the ANGPTL3 gene in two families diagnosed of familial hypobetalipoproteinemia without APOB mutation. Clin. Chim. Acta 413, 552–555 (2012).
   Google Scholar
• Robciuc MR, Maranghi M, Lahikainen A et al. Angptl3 deficiency is associated with increased insulin sensitivity, lipoprotein lipase activity, and decreased serum free fatty acids. Arterioscler. Thromb. Vasc. Biol. 33 (7), 1706–1713 (2013). ▪▪ Demonstrates, for the first time, in a large cohort of FHBL2 subjects, that complete Angptl3 deficiency is associated with markedly reduced LPL activity and serum FFA levels, and decreased values of Homeostasis Model of Assessment – Insulin Resistance as an index of insulin sensitivity. Also describes lipoprotein composition and size in FHBL2 subjects as compared with controls.
   Google Scholar
• Shimamura M, Matsuda M, Yasumo H, et al. Angiopoietin-like protein3 regulates plasma HDL cholesterol through suppression of endothelial lipase. Arterioscler. Thromb. Vasc. Biol. 27, 366–372 (2007). ▪▪ Demonstrates, for the first time, in vitro and in mice, that Angptl3 inhibits the endothelial lipase, through a putative heparin-binding site in the N-terminal domain of Angptl3, hence decreasing plasma HDL levels. Furthermore, they established an ELISA system for human Angptl3 and found that plasma Angptl3 levels significantly correlated with plasma HDL cholesterol and HDL-phospholipid levels in human subjects.
   Google Scholar
• Minicocci I, Cantisani V, Poggiogalle E et al. Functional and morphological vascular changes in subjects with familial combined hypolipidemia: an exploratory analysis. Int. J. Cardiol. pii: S0167-5273(13)00962-5 (2013). ▪▪ For the first time, describes carotid intima–media thickness measures in FHBL2 individuals as compared with controls. They also studied scavenger receptor BI-mediated cholesterol efflux to sera derived from FHBL2 homozygous individuals as compared with controls.
   Google Scholar
• Teslovich TM, Musunuru K, Smith AV et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 466, 707–713 (2010).
   Google Scholar
• Angelakopoulou A, Shah T, Sofat R et al. Comparative analysis of genome-wide association studies signals for lipids, diabetes, and coronary heart disease: Cardiovascular Biomarker Genetics Collaboration. Eur. Heart. J. 33, 393–407 (2012). ▪▪ In a genome-wide association study, the authors found that ANGPTL3 rs12042319 was associated with coronary heart disease risk (odds ratio: 1.11; 95% CI: 1.03–1.19).
   Google Scholar
• Romeo S, Yin W, Kozlitina J et al. Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. J. Clin. Invest. 119, 70–79 (2009).
   Google Scholar
• Robciuc MR, Tahvanainen E, Jauhiainen M et al. Quantitation of serum angiopoietin-like proteins 3 and 4 in a Finnish population sample. J. Lipid. Res. 51, 824–831(2010).
   Google Scholar
• Hatsuda S, Shoji T, Shinohara K et al. Association between plasma angiopoietin-like protein 3 and arterial wall thickness in healthy subjects. J. Vasc. Res. 44(1), 61–66 (2007).
   Google Scholar